This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Natural Hormone Replacement Pioneer Challenges Incomplete Testosterone Studies

DALLAS, Nov. 8, 2013 /PRNewswire/ -- BioTE Medical Founder Dr. Gary Donovitz today challenged recent reports that have been critical of testosterone replacement therapy.   Media coverage has reported that testosterone replacement therapy was over-prescribed by physicians, often unnecessary and in some cases dangerous for consumers.     

(Photo: http://photos.prnewswire.com/prnh/20131108/DA13647)

Dr. Donovitz, whose company BioTE Medical is a leading provider of natural hormone replacement therapy using subcutaneous pellets, was critical of what he called a general lack of depth in research. Donovitz said, "We see significant flaws in the information that's being presented to the public. Studies based solely on pharmaceutical products are being applied to all testosterone therapy.  As a result, credible research which is essential to a full understanding of testosterone therapy has not been considered."    

The Wall Street Journal on November 6, 2013 published an article that was critical of testosterone replacement therapy.  The publication cited a research study of veterans which claimed that testosterone therapy raised the risk of heart attack and stroke by about 30%.  Because the focus of the study was limited to pharmaceutical products, Dr. Donovitz said the research and its conclusions are flawed and incomplete.  Dr. Donovitz added, "The study referenced in the Wall Street Journal article is limited to the synthetic gels, patches and shots which are being heavily promoted on television and radio.  These pharmaceutical products use synthetic hormones and we've known about the dangers of synthetics for years.  However, to be accurate and complete, any study of testosterone therapy needs to also include data for natural hormone replacement. "

In addition to calling the Wall Street Journal research incomplete, Dr. Donovitz said that the study had other issues that impacted its integrity. According to Donovitz, many of the 23,173 veterans that were excluded from the study would have benefitted from proper testosterone optimization using natural hormone replacement.  Donovitz also expressed concern that the sample, which consisted of elderly men, was skewed because of a high incidence of conditions such as hypertension, diabetes and hyperlipidemia.  Another anomaly of the study, according to Donovitz, is the fact that of the 1223 skewed patients prescribed testosterone gels, patches and creams, only 20% filled one prescription.   Donovitz added, "The level of patient monitoring and care after the procedure was not sufficient.  60% of the patients administered testosterone had follow up laboratory assessments of their serum testosterone.  You cannot expect results without optimization and that requires laboratory assessment." 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,117.01 +105.07 0.58%
S&P 500 2,115.80 +6.20 0.29%
NASDAQ 5,101.6050 +25.0810 0.49%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs